In double emulsion W/O/W solvent extraction runs for leuprolide acetate and octreotide acetate microspheres, acid-terminated low-inherent-viscosity poly(DL-lactide) (PURASORB PDL 02A) is introduced into the dispersed oil phase at 10–20 wt% relative to dichloromethane, with drug:polymer ratios maintained between 1:10 and 1:50 depending on whether an initial burst below 15% or a lag phase of 7–14 days is required. The primary W/O emulsion is formed under rotor–stator high shear at 5,000–15,000 rpm on a Silverson L5M-A mixer, producing internal aqueous droplet diameters of 0.5–2.0 µm; this pre-emulsion is then transferred through an in-line static mixer into a chilled continuous phase containing 1–5 wt% polyvinyl alcohol and 0.1–0.5 wt% sodium chloride to balance osmotic pressure. Hardening proceeds in a jacketed stirred tank maintained at 15–20 °C under reduced pressure (150–300 mbar), where residual dichloromethane is drawn below ICH Q3C limits of 600 ppm prior to lyophilization. Compliance is anchored to USP <790> for visible particulate control, USP <921> for cake moisture below 0.5%, and ISO 10993-5:2009 for cytotoxicity of the finished microsphere vials. Terminal product formats include single-dose lyophilized vials containing 10–50 µm mean-diameter microspheres for intramuscular or subcutaneous injection, and dual-chamber syringes in which the microsphere cake and aqueous diluent are separated until point of care. Production-scale experience indicates that batch-to-batch particle size drift occurs when continuous-phase temperature exceeds 15 °C, making chilled surfactant feed jackets and on-line laser diffraction controls mandatory for lot uniformity.

Why Does Acid Termination Shift the Viscosity Profile in NMP-Based Depot Vehicles?

For subcutaneous in situ forming implant syringes prepared with acid-terminated DL-lactide and N-methyl-2-pyrrolidone, polymer concentrations of 30–50 wt% are dissolved at 40–60 °C under low-speed anchor stirring in a glass-lined vessel until a clear, air-free solution is obtained. The terminal carboxylic acid group on the PDLLA chain lowers solution pH relative to ester-terminated batches by approximately 0.5–1.0 unit, which alters the solvent exchange rate during phase inversion and must be checked for acid-labile peptides. Addition ratios for the active compound typically range from 5–15 wt% relative to total solution mass, with syringe fill volumes of 3–10 mL and needle gauges of 21G–25G. The production line uses a nitrogen-purged filling isolator with dew point below -40 °C because residual moisture above 0.1 wt% in NMP causes viscosity drift beyond 1.2 Pa·s at 25 °C, after which injection force through a 25G needle exceeds 15 N and becomes unacceptable for patient self-administration. Terminal product types include in situ forming implant syringes for subcutaneous depot injection, cartridge-based pen injector systems, and veterinary long-acting antibiotic depots where the polymer solution is mixed with the active at the time of administration. Regulatory acceptance relies on ISO 10993-6:2016 for local intramuscular reaction, ISO 10993-18:2020 for chemical characterization of leachables, 21 CFR 210 and 211 for aseptic processing, and ICH Q3C for NMP and dimethyl sulfoxide extractables reported in the finished device.

When hydrophobic actives with logP values above 4.0 are formulated as poly(DL-lactide) nanoparticles, the acid-terminated grade with a nominal IV of 0.2 dL/g is dissolved with the API in acetone or acetonitrile at a polymer concentration of 1–10 mg/mL, using drug:polymer ratios of 1:5 to 1:20. The organic phase is displaced into an aqueous continuous phase containing 0.1–0.5 wt% polysorbate 80 or polyvinyl alcohol under high-pressure homogenization at 50–150 MPa in a Microfluidizer M-110P, followed by rotary evaporation at 30–40 °C to reduce residual solvent below ICH Q3C acceptance criteria, typically 0.5% w/w in the final dispersion. Tangential flow filtration against polyethersulfone membranes with a molecular weight cutoff of 100–300 kDa removes free drug and excess surfactant, reducing the polydispersity index below 0.15 when measured by ISO 22412:2017 dynamic light scattering. Terminal product types include lyophilized nanoparticle vials for intravenous infusion after reconstitution with water for injection or 5% dextrose, and carbodiimide-coupled targeting ligand nanoparticle kits that exploit the terminal carboxylic acid group for surface conjugation. Compliance for the lyophilized intermediate requires USP <790> for visible particulate control and ISO 10993-5:2009 for in vitro cytotoxicity; for folate- or antibody-conjugated batches, size-exclusion chromatography must confirm soluble aggregate content below 5%. Production-scale failure modes include uncontrolled antisolvent addition raising the aqueous phase temperature above 10 °C, which pushes the Z-average diameter outside 80–200 nm and increases vial-to-vial variation beyond release limits.

Hot-Melt Extrusion Below 110 °C Requires Dew-Point-Control on Standard Twin-Screw Lines

The thermal processing window of low-IV acid-terminated PDLLA is bounded by a glass transition midpoint near 40–50 °C as determined by ASTM D3418-21 and an upper limit of approximately 110 °C, above which inherent viscosity loss exceeds 10% within 10 min residence time due to hydrolysis catalyzed by residual moisture and terminal acid groups. Formulations for hot-melt extruded implant rods typically contain 60–85 wt% polymer, 10–30 wt% micronized active, and 5–10 wt% triethyl citrate as a plasticizing processing aid to stabilize screw torque below 8 N·m on a Leistritz ZSE 18 HP co-rotating twin-screw extruder with an L/D ratio of 40:1. Granules are pre-dried in a desiccant-wheel dryer to residual moisture below 0.1%, transferred under nitrogen purge at 2–5 L/min to the hopper, and extruded through strand dies of 0.5–2.0 mm diameter into a chilled air knife and pelletizer. Downstream rod cutting, vacuum packaging in aluminum-foil pouches, and terminal gamma sterilization at 25 kGy complete the process; gamma irradiation must be validated because chain scission of the low-molecular-weight acid-terminated PDLLA can reduce inherent viscosity by an additional 5–15% and shorten the release plateau. Terminal product configurations include pre-loaded trocars containing 2.0 mm diameter rods of 20–40 mm length for subcutaneous hormone therapy, and multi-rod blister trays for post-surgical analgesia. Regulatory acceptance relies on ISO 10993-6:2016 for intramuscular implantation, ASTM F1635-16 for in vitro hydrolytic degradation, and 21 CFR 211 for aseptic handling of terminally sterilized implants.

Intravitreal Insert Processing and Ocular Particulate Limits Under USP <789>

For intravitreal drug delivery of corticosteroids or small-molecule anti-angiogenic agents, acid-terminated PDLLA inserts with total mass between 0.5 mg and 3.0 mg are manufactured at drug:polymer ratios of 1:10 to 1:20, either by micro injection molding in polished mold cavities with 50–100 kN clamp force or by acetone solvent casting followed by laser cutting to 0.7–1.5 mm diameter discs. Micro injection molding employs barrel temperatures of 80–110 °C and injection speeds below 100 mm/s to prevent jetting, sink marks, and void formation; solvent-cast routes require cleanroom dew points below 10 °C because acetone residue above 0.5% causes laminate delamination after insertion. The carboxylic acid end groups of this low-IV PDLLA can interact electrostatically with positively charged anti-VEGF antibody fragments; size-exclusion chromatography is therefore run during excipient compatibility screening to keep soluble aggregate content below 5% before locking a formulation. Release testing follows USP <789> for ophthalmic particulate limits, ISO 10993-5:2009 for retinal pigment epithelial cell cytotoxicity, and ICH Q3C for residual acetone; finished injectors are limited to not more than 10 particles per mL at 10 µm or larger. Terminal product configurations include pre-loaded 22G–27G injectors for office-based intravitreal implantation, and single-rod ethylene oxide sterilized pouches conditioned at 38 °C and 60% relative humidity. Manufacturing experience shows that micro-mold surface roughness above Ra 0.2 µm increases ejection force and produces edge cracks that elevate particulate counts in USP <789> release testing.

If a 90-day subcutaneous depot is required without the use of polar aprotic solvents, compression-molded rods from acid-terminated PDLLA are compressed at 60–90 °C and 10–20 kN for 1–5 min in a Carver hydraulic press fitted with PTFE-lined mold cavities. Formulations combine 70–90 wt% polymer, 5–15 wt% active, and 5–10 wt% sodium chloride or poloxamer 188 as a porogen to modulate the lag phase; drug:polymer ratios below 1:5 are avoided because the low-molecular-weight acid-terminated PDLLA forms a tacky mass that cannot be ejected from the mold without deformation. Pre-blending in a low-shear tumble mixer at 20 rpm for 30–60 min ensures homogeneous distribution, while compression tooling is cooled to 25 °C before ejection. Rods are cut to 1.5–2.5 mm diameter and 10–40 mm length and then loaded into implant trocars under horizontal laminar flow. In vivo acceptance is anchored to ISO 10993-6:2016 for subcutaneous implantation, ISO 10993-10:2010 for sensitization, and ASTM F1635-16 for in vitro mass loss; terminal gamma irradiation at 25 kGy is validated to maintain a sterility assurance level below 10^-6. Terminal product types include veterinary hormonal implants in multi-dose cartridge injectors, and human subcutaneous rods for chronic hormone therapy where daily oral dosing is contraindicated. Published production-scale data for this specific compression-molded configuration using the acid-terminated grade remain limited, so pilot-scale verification of compact hardness, release consistency, and residual moisture below 0.5% is required before commercial batch setting.